Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study)

Ayman M. Mousa

doi:doi:10.11648/j.ijcda.20160203.11

| Peer-Reviewed

Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study)

Ayman M. Mousa

Published in International Journal of Clinical and Developmental Anatomy (Volume 2, Issue 3)

Received: 26 May 2016 Accepted: 3 June 2016 Published: 12 June 2016

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Bleomycin is a chemotherapeutic agent commonly used to treat curable diseases such as Hodgkin’s lymphoma. The major limitation of bleomycin therapy is the pulmonary toxicity. Pirfenidone is a modified phenyl pyridine that has an antioxidant, anti-transforming growth factor and anti-platelet derived growth factor effects. Aim of the study: to evaluate the histological, immunohistochemical and biochemical changes in the pulmonary alveoli of adult male albino rats after intake of bleomycin and the possible role of pirfenidone in minimizing these changes. Material and Methods: Forty adult male albino rats were used in this study. They were divided equally into 4 equal groups; the first group (control), the second group that received bleomycin for 10 days, the third group that received pirfenidone for 10 days and the fourth group that received pirfenidone & bleomycin for 10 days. The lungs were dissected out, processed and lung sections were stained with Hx&E, Masson's trichrome and immunohistochemicaly. Then they were examined by light microscope for histological and immuno-histochemical study to evaluate the structure of pulmonary alveoli. Biochemical measurement of malondialdehyde (MDA), glutathione peroxidase (GSH-Px) and tumor necrosis factor-α (TNF-α) were also performed. Results: Bleomycin treatment in the second group induced alveolar inflammation, interstitial pulmonary inflammation and pulmonary alveolar fibrosis, while pirfenidone significantly reduced these induced lung injuries in the fourth group rats that treated with pirfenidone and bleomycin. These protective effects were associated with a significant (P<0.05) reduction in the levels of MDA, and TNF-α associated with a significant (P<0.05) increase in the levels of GSH-P in the homogenate of lung tissue compared with the second group. Conclusion: The present study showed a protective effect of pirfenidone on the structure of pulmonary alveoli subjected to bleomycin intake. So intake of pirfenidone with bleomycin is advised for treatment of pulmonary alveolar toxicity.

Published in	International Journal of Clinical and Developmental Anatomy (Volume 2, Issue 3)
DOI	10.11648/j.ijcda.20160203.11
Page(s)	17-23
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Bleomycin, Pirfenidone, Pulmonary Fibrosis, Inflammatory Cytokines

References

[1]	Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q, Zhang S, Wang W, Chen X, Wang J: Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis: European Journal of Pharmacology. 2010, 627: 304–312.
[2]	Abd El Salam NF, Hafez MS, Omar SM and El Sayed HF: The role of bone marrow-derived mesenchymal stem cells in a rat model of paraquat-induced lung fibrosis: a histological and immunohistochemical study. The Egyptian Journal of Histology. 2015, 38: 389-401.
[3]	Reinert T, Baldotto C, Nunes F and Scheliga A: Bleomycin-Induced Lung Injury. Journal of Cancer Research. 2013, 13: 1-9. Article ID 480608.
[4]	Wang Z, Guo Q, Zhang X, Li X, Li W, Ma X and Ma L: Corilagin Attenuates Aerosol Bleomycin-Induced Experimental Lung Injury. Int. J. Mol. Sci. 2014, 15: 9762-9779.
[5]	Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S and Hardie WD: MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am. J Respir Cell Mol Biol. 2012; 46:380-8.
[6]	Hilberg O, Simonsen U, du Bois R and Bendstrup E.: Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin. Respir.J.2012; 6: 131–143.
[7]	Lopez DA, SanchezRC, Montoya B M, Sanchez ES, Lucano LS, Macias BJ, Armendariz B J: Role and New Insights of Pirfenidone in Fibrotic Diseases. Int J Med Sci 2015; 12(11): 840-847.
[8]	El-Gamal MA, Zaitone SA and Moustafa YM: Role of irbesartan in protection against pulmonary toxicity induced by bleomycin in rats. IOSR Journal Of Pharmacy. 2013; 3: 38-47.
[9]	Chen JF, Ni HF, Pan MM, Liu H, Xu M, Zhang MH, Liu BC: Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol (2012). 14(6):676-85 doi:10.1152/ajprenal.00507.2012.
[10]	Bancroft JD, Layton C. The hematoxylin and eo¬sin, connective and mesenchymal tissues with their stains In: Suvarna SK, Layton C and Bancroft JD, editors. Bancroft’s Theory and practice of histological techniques. 7th edition. Churchill Livingstone: Philadelphia; 2013. pp. 173-212.
[11]	Simon G. Royce, Matthew Shen, Krupesh P. Patel, BrookeM. Huuskes,Sharon D. Ricardo, and Chrishan S. Samuel: Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease. Stem Cell Research 15 (2015) 495–505.
[12]	Valenzuela A. The biological significance of malondialdehvde determination in the assessment of tissue oxidative stress?. Life Sci., 1991:48:301-309.
[13]	Ovize M., Baxter G. F., Di L. F., Ferdinandy P., Garcia-Dorado D., and Hausenloy D. J. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the Euro¬pean Society of Cardiology. Cardiovasc. Res. (2010); 87(1): 406–423. http://dx.doi.org/10.1093/cvr/cvq129
[14]	Francis J., Chu Y., Johnson A. K., Weiss R. M., Felder R. B. Acute myocardial infarction induces hypothalamic cytokine synthesis. Am. J. Physiol. Heart Circ. Physiol. (2004); 286(1):2264–2271.
[15]	El-Morsy AA, Al-Shathly MR: Evaluation of the anti-proliferative and immuomodulatory effect of sallyl cysteine on pulmonary fibrosis induced-rats. International Journal of Plant, Animal and Environmental Sciences. 2014, 4(2): 357-371.
[16]	Skurikhin EG, Pershina OV, Reztsova AM, Ermakova NN, Khmelevskaya ES, Krupin VA, Stepanova IE, Artamonov AV, Bekarev AA, Madonov PG, Dygai AM.: Modulation of bleomycin-induced lung fibrosis by pegylated hyaluronidase and dopamine receptor antagonist in mice. PLoS One. 2015;10(4): 0125065.
[17]	Salem MY, El-Azab NE-E and Faruk EM: Modulatory effects of green tea and aloe vera extracts on experimentally-induced lung fibrosis in rats: histological and immunohistochemical study. Journal of Histology & Histopathology 2014, 1(6): 1-7.
[18]	Sabry MM, Elkalawy SA, Abo-Elnour RK, El-Maksod DF: Histological and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat. International Journal of Stem Cells 2014; 7: 33-42.
[19]	Arafat EM, Ghoneim FM, Elsamanoudy AZ: Fibrogenic gene expression in the skin and lungs of animal model of systemic sclerosis: A histological, immunohistochemical and molecular study. The Egyptian Journal of Histology. 2015, 38: 21-31.
[20]	Zhu B, Ma AQ, Yang L and Dang XM: Atorvastatin Attenuates Bleomycin-Induced Pulmonary Fibrosis via suppressing iNOS Expression and the CTGF (CCN2)/ERK Signaling Pathway. Int. J. Mol. Sci. 2013, 14, 24476-24491.
[21]	Nergiz HT, Haki K, Sahende E, Koksal D, Huseyin G, and Emre A: The protective effect of naringin against bleomycin-induced pulmonary fibrosis in Wistar rats. Pulmonary Medicine. 2016; 16(1):1-12. Article ID 7601393.
[22]	Ermis H, Parlakpinar H, Gulbas G: Protective effect of dexpanthenol on bleomycin induced pulmonary fibrosis in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013. 386(12): 1103–1110.
[23]	Moore BB, Lawson WE, Oury TD, Sisson TS, Raghavendran K, and Hogaboam CM: Animal models of fibrotic lung disease. American Journal of Respiratory Cell and Molecular Biology. 2013, 49(2): 167–179.
[24]	Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD and Kossen K: Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 2011; 20(120): 85–97.
[25]	Barragán JM, Rodríguez AS, Partida JN, Borunda JA: The multifaceted role of pirfenidone and its novel targets. Fibrogenesis & Tissue Repair. 2010; 3(16):1-11.
[26]	Hilberg O, Simonsen U, Bois R and Bendstrup E: Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. The Clinical Respiratory Journal. 2012; 131-143.
[27]	Myllarniemi M and Kaarteenaho R: Pharmacological treatment of idiopathic pulmonary fibrosis − preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. European Clinical Respiratory Journal. 2015; 26 (2): 1-10.

Cite This Article

Plain Text BibTeX RIS

APA Style

Ayman M. Mousa. (2016). Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study). International Journal of Clinical and Developmental Anatomy, 2(3), 17-23. https://doi.org/10.11648/j.ijcda.20160203.11

Copy | Download

ACS Style

Ayman M. Mousa. Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study). Int. J. Clin. Dev. Anat. 2016, 2(3), 17-23. doi: 10.11648/j.ijcda.20160203.11

Copy | Download

AMA Style

Ayman M. Mousa. Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study). Int J Clin Dev Anat. 2016;2(3):17-23. doi: 10.11648/j.ijcda.20160203.11

Copy | Download

@article{10.11648/j.ijcda.20160203.11,
  author = {Ayman M. Mousa},
  title = {Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study)},
  journal = {International Journal of Clinical and Developmental Anatomy},
  volume = {2},
  number = {3},
  pages = {17-23},
  doi = {10.11648/j.ijcda.20160203.11},
  url = {https://doi.org/10.11648/j.ijcda.20160203.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcda.20160203.11},
  abstract = {Introduction: Bleomycin is a chemotherapeutic agent commonly used to treat curable diseases such as Hodgkin’s lymphoma. The major limitation of bleomycin therapy is the pulmonary toxicity. Pirfenidone is a modified phenyl pyridine that has an antioxidant, anti-transforming growth factor and anti-platelet derived growth factor effects. Aim of the study: to evaluate the histological, immunohistochemical and biochemical changes in the pulmonary alveoli of adult male albino rats after intake of bleomycin and the possible role of pirfenidone in minimizing these changes. Material and Methods: Forty adult male albino rats were used in this study. They were divided equally into 4 equal groups; the first group (control), the second group that received bleomycin for 10 days, the third group that received pirfenidone for 10 days and the fourth group that received pirfenidone & bleomycin for 10 days. The lungs were dissected out, processed and lung sections were stained with Hx&E, Masson's trichrome and immunohistochemicaly. Then they were examined by light microscope for histological and immuno-histochemical study to evaluate the structure of pulmonary alveoli. Biochemical measurement of malondialdehyde (MDA), glutathione peroxidase (GSH-Px) and tumor necrosis factor-α (TNF-α) were also performed. Results: Bleomycin treatment in the second group induced alveolar inflammation, interstitial pulmonary inflammation and pulmonary alveolar fibrosis, while pirfenidone significantly reduced these induced lung injuries in the fourth group rats that treated with pirfenidone and bleomycin. These protective effects were associated with a significant (P<0.05) reduction in the levels of MDA, and TNF-α associated with a significant (P<0.05) increase in the levels of GSH-P in the homogenate of lung tissue compared with the second group. Conclusion: The present study showed a protective effect of pirfenidone on the structure of pulmonary alveoli subjected to bleomycin intake. So intake of pirfenidone with bleomycin is advised for treatment of pulmonary alveolar toxicity.},
 year = {2016}
}

Copy | Download

TY - JOUR
T1 - Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study)
AU - Ayman M. Mousa
Y1 - 2016/06/12
PY - 2016
N1 - https://doi.org/10.11648/j.ijcda.20160203.11
DO - 10.11648/j.ijcda.20160203.11
T2 - International Journal of Clinical and Developmental Anatomy
JF - International Journal of Clinical and Developmental Anatomy
JO - International Journal of Clinical and Developmental Anatomy
SP - 17
EP - 23
PB - Science Publishing Group
SN - 2469-8008
UR - https://doi.org/10.11648/j.ijcda.20160203.11
AB - Introduction: Bleomycin is a chemotherapeutic agent commonly used to treat curable diseases such as Hodgkin’s lymphoma. The major limitation of bleomycin therapy is the pulmonary toxicity. Pirfenidone is a modified phenyl pyridine that has an antioxidant, anti-transforming growth factor and anti-platelet derived growth factor effects. Aim of the study: to evaluate the histological, immunohistochemical and biochemical changes in the pulmonary alveoli of adult male albino rats after intake of bleomycin and the possible role of pirfenidone in minimizing these changes. Material and Methods: Forty adult male albino rats were used in this study. They were divided equally into 4 equal groups; the first group (control), the second group that received bleomycin for 10 days, the third group that received pirfenidone for 10 days and the fourth group that received pirfenidone & bleomycin for 10 days. The lungs were dissected out, processed and lung sections were stained with Hx&E, Masson's trichrome and immunohistochemicaly. Then they were examined by light microscope for histological and immuno-histochemical study to evaluate the structure of pulmonary alveoli. Biochemical measurement of malondialdehyde (MDA), glutathione peroxidase (GSH-Px) and tumor necrosis factor-α (TNF-α) were also performed. Results: Bleomycin treatment in the second group induced alveolar inflammation, interstitial pulmonary inflammation and pulmonary alveolar fibrosis, while pirfenidone significantly reduced these induced lung injuries in the fourth group rats that treated with pirfenidone and bleomycin. These protective effects were associated with a significant (P<0.05) reduction in the levels of MDA, and TNF-α associated with a significant (P<0.05) increase in the levels of GSH-P in the homogenate of lung tissue compared with the second group. Conclusion: The present study showed a protective effect of pirfenidone on the structure of pulmonary alveoli subjected to bleomycin intake. So intake of pirfenidone with bleomycin is advised for treatment of pulmonary alveolar toxicity.
VL - 2
IS - 3
ER -

Copy | Download

Author Information

Ayman M. Mousa

Department of Histology and Cell Biology, Benha Faculty of Medicine, Benha University, Cairo, Egypt; Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, KSA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ayman M. Mousa. (2016). Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study). International Journal of Clinical and Developmental Anatomy, 2(3), 17-23. https://doi.org/10.11648/j.ijcda.20160203.11

Copy | Download

ACS Style

Ayman M. Mousa. Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study). Int. J. Clin. Dev. Anat. 2016, 2(3), 17-23. doi: 10.11648/j.ijcda.20160203.11

Copy | Download

AMA Style

Ayman M. Mousa. Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study). Int J Clin Dev Anat. 2016;2(3):17-23. doi: 10.11648/j.ijcda.20160203.11

Copy | Download

@article{10.11648/j.ijcda.20160203.11,
  author = {Ayman M. Mousa},
  title = {Effect of Pirfenidone on Bleomycin Induced Pulmonary Alveolar Fibrosis in Adult Male Rats (Histological, Immunohistochemical, Morphometrical and Biochemical Study)},
  journal = {International Journal of Clinical and Developmental Anatomy},
  volume = {2},
  number = {3},
  pages = {17-23},
  doi = {10.11648/j.ijcda.20160203.11},
  url = {https://doi.org/10.11648/j.ijcda.20160203.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcda.20160203.11},
  abstract = {Introduction: Bleomycin is a chemotherapeutic agent commonly used to treat curable diseases such as Hodgkin’s lymphoma. The major limitation of bleomycin therapy is the pulmonary toxicity. Pirfenidone is a modified phenyl pyridine that has an antioxidant, anti-transforming growth factor and anti-platelet derived growth factor effects. Aim of the study: to evaluate the histological, immunohistochemical and biochemical changes in the pulmonary alveoli of adult male albino rats after intake of bleomycin and the possible role of pirfenidone in minimizing these changes. Material and Methods: Forty adult male albino rats were used in this study. They were divided equally into 4 equal groups; the first group (control), the second group that received bleomycin for 10 days, the third group that received pirfenidone for 10 days and the fourth group that received pirfenidone & bleomycin for 10 days. The lungs were dissected out, processed and lung sections were stained with Hx&E, Masson's trichrome and immunohistochemicaly. Then they were examined by light microscope for histological and immuno-histochemical study to evaluate the structure of pulmonary alveoli. Biochemical measurement of malondialdehyde (MDA), glutathione peroxidase (GSH-Px) and tumor necrosis factor-α (TNF-α) were also performed. Results: Bleomycin treatment in the second group induced alveolar inflammation, interstitial pulmonary inflammation and pulmonary alveolar fibrosis, while pirfenidone significantly reduced these induced lung injuries in the fourth group rats that treated with pirfenidone and bleomycin. These protective effects were associated with a significant (P<0.05) reduction in the levels of MDA, and TNF-α associated with a significant (P<0.05) increase in the levels of GSH-P in the homogenate of lung tissue compared with the second group. Conclusion: The present study showed a protective effect of pirfenidone on the structure of pulmonary alveoli subjected to bleomycin intake. So intake of pirfenidone with bleomycin is advised for treatment of pulmonary alveolar toxicity.},
 year = {2016}
}

Copy | Download